Sanctuary Advisors LLC Sells 9,461 Shares of Vaxcyte, Inc. $PCVX

Sanctuary Advisors LLC reduced its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 67.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,669 shares of the company’s stock after selling 9,461 shares during the period. Sanctuary Advisors LLC’s holdings in Vaxcyte were worth $215,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Allworth Financial LP lifted its holdings in Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after purchasing an additional 731 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in Vaxcyte during the 3rd quarter valued at about $45,000. CIBC Private Wealth Group LLC lifted its holdings in Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after purchasing an additional 1,350 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Vaxcyte during the 3rd quarter valued at about $72,000. Finally, Danske Bank A S bought a new position in Vaxcyte during the 3rd quarter valued at about $76,000. 96.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on PCVX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. BTIG Research lifted their price objective on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Guggenheim reiterated a “buy” rating and issued a $116.00 price objective on shares of Vaxcyte in a research report on Monday, February 2nd. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Vaxcyte presently has an average rating of “Moderate Buy” and an average target price of $86.00.

Vaxcyte Price Performance

PCVX opened at $54.03 on Wednesday. The company has a market cap of $7.80 billion, a price-to-earnings ratio of -7.85 and a beta of 1.30. The firm has a 50 day simple moving average of $57.93 and a 200 day simple moving average of $52.07. Vaxcyte, Inc. has a fifty-two week low of $28.64 and a fifty-two week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period last year, the company earned ($1.04) EPS. As a group, analysts expect that Vaxcyte, Inc. will post -7.85 EPS for the current year.

Insider Transactions at Vaxcyte

In related news, COO Jim Wassil sold 2,250 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $56.83, for a total value of $127,867.50. Following the completion of the sale, the chief operating officer owned 160,744 shares in the company, valued at approximately $9,135,081.52. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of the company’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total value of $180,000.00. Following the completion of the sale, the chief accounting officer owned 28,975 shares of the company’s stock, valued at $1,738,500. This represents a 9.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 17,037 shares of company stock valued at $994,899 in the last quarter. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.